deferiprone has been researched along with Mucorales Infection in 3 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice." | 7.73 | Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006) |
| "The increased risk of mucormycosis in patients with renal failure receiving deferoxamine iron chelation therapy is explained by the fact that deferoxamine actually acts as a siderophore for the agents of mucormycosis, supplying previously unavailable iron to the fungi." | 4.84 | Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. ( Edwards, J; Ibrahim, AS; Spellberg, B, 2008) |
| " In addition, we compared the efficacy of deferiprone with that of liposomal amphotericin B (LAmB) in treating mucormycosis in diabetic ketoacidotic mice." | 3.73 | Deferiprone iron chelation as a novel therapy for experimental mucormycosis. ( Edwards, JE; Fu, Y; Ibrahim, AS; Spellberg, B, 2006) |
| "Deferoxamine (DFO), when used in dialysis patients, is a well recognized risk factor for the development of mucormycosis caused by Rhizopus." | 3.69 | Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. ( Boelaert, JR; Crichton, RR; de Locht, M; Schneider, YJ; Van Cutsem, J, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, AS | 2 |
| Spellberg, B | 2 |
| Edwards, J | 1 |
| Edwards, JE | 1 |
| Fu, Y | 1 |
| Boelaert, JR | 1 |
| Van Cutsem, J | 1 |
| de Locht, M | 1 |
| Schneider, YJ | 1 |
| Crichton, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study[NCT00419770] | Phase 2 | 20 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00419770)
Timeframe: 30 Days After End of Therapy
| Intervention | Events (Number) |
|---|---|
| Deferasirox | 16 |
| Placebo | 16 |
1 review available for deferiprone and Mucorales Infection
| Article | Year |
|---|---|
Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Microbia | 2008 |
2 other studies available for deferiprone and Mucorales Infection
| Article | Year |
|---|---|
Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Deferiprone; Diabetic Ketoacidosis; Humans; Iron Chelati | 2006 |
Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
Topics: Animals; Deferiprone; Deferoxamine; Guinea Pigs; Iron; Iron Chelating Agents; Male; Mucormycosis; Py | 1994 |